The Mas protooncogene encodes a G protein-coupled receptor that has been described as a functional receptor for the cardioprotective fragment of the renin-angiotensin system (RAS), Angiotensin (Ang)-(1-7). The aim of this current study was to evaluate the responsiveness of Mas expression in hearts during different physiological and pathological conditions in rats. Physical training was considered a physiological condition, while isoproterenol-induced hypertrophy, myocardial infarction and DOCA-salt model of hypertension were used as pathological models of heart injury. The expression of Mas was analyzed by western blotting. Although swim-trained rats presented significant cardiac hypertrophy, our physical training protocol was unable to induce changes in the expression of Mas. On the other hand, cardiac hypertrophy and damage elicited by isoproterenol treatment led to a reduction in Mas expression. Myocardial infarction also significantly decreased the expression of Mas after 21 days of myocardial ischemia. Additionally, Mas expression levels were increased in hearts of DOCA-salt rats. Our present data indicate that Mas expression is responsive to different pathological stimuli, thereby suggesting that Mas receptor is involved in the homeostasis of the heart, as well as in the establishment and progression of cardiac diseases.
Introduction
It has become apparent that the biologically active member of the renin-angiotensin system (RAS), the heptapeptide Angiotensin (Ang)-(1-7), holds cardioprotective actions [4, 5, 18, 23] . This peptide is formed through the degradation of Ang II by the angiotensinconverting enzyme (ACE) homolog, ACE2, yet other enzymes such as the metallopeptidase neprilysin are also able to produce Ang-(1-7) directly from Ang I [23] . However, recent reports have indicated that ACE2 is the principal enzyme and pathway involved in the Ang-(1-7) generation in key organs as heart and kidney [11, 26] . Under physiological and pathological states, it is now recognized that Ang-(1-7) opposes many cardiac actions of Ang II by binding to the Mas receptor [22] , and triggering signaling pathways leading to vasodilation, anti-fibrotic, anti-hypertrophic and anti-arrhythmic actions [5, 8, 23] .
Functionally, the confirmation that Mas is a receptor for Ang-(1-7) came from mice which present genetic deletion of this receptor (Mas knockout mice). For example, the vasodilator effect of Ang-(1-7) is absent in these mice [13] . Moreover, Mas knockout mice showed pronounced impairment of the cardiac [3, 24] and renal functions [16] and Mas deficiency leads to dramatic changes in glucose and lipid metabolisms, inducing a metabolic syndrome-like state [25] .
It is known that the expression and/or activity of the major enzymes, peptides and receptors of the RAS change according to different pathophysiological conditions of the heart. Furthermore, these changes depend on the stage of the disease. For example, Ishiyama et al. [10] found a reduction in AT 1 expression in the chronic phase of the myocardial infarction (MI)-induced cardiac remodeling (28 days). Importantly, these alterations occurred without modifications of cardiac ACE and ACE2 mRNA levels. In addition, Ocaranza et al. [15] observed an increase in cardiac ACE2 activity after 1 week of MI followed by a reduction in its activity after 8 weeks of the injury. Reduced cardiac expression of AT 2 was also observed in the early post injury period in infarcted hearts, but not at the later failure stage [12] . Previous studies have also investigated the levels of Ang II and Ang-(1-7) in the injured heart. While Zhang et al. [27] reported an increase in Ang I and Ang II immunoreactivity in the heart of adult rats after 7 days of coronary artery narrowing, Santiago et al. [21] found no significant differences in Ang-(1-7) levels in the left ventricles of DOCA-salt hypertensive rats when compared to their controls. Together, these studies support the notion that expression levels of members of the RAS are regulated independently in order to maintain cardiac homeostasis.
In addition to ACE2 and Ang-(1-7), Mas is part of the cardioprotective axis of the RAS, therefore it is of major importance to determine whether cardiac Mas expression is modulated at distinct physiological and pathological conditions. In our recent report, we have submitted Wistar rats and spontaneously hypertensive rats (SHRs) to a physical training protocol. Interestingly, only SHR presented an increase in left ventricular Mas expression in response to exercise training [9] , indicating that cardiac Mas expression can be regulated not only according to the stimulus, physiological or pathological, but also according to the state of the animal, i.e. healthy or diseased. Therefore, the aim of this study was to evaluate the responsiveness of Mas expression in rat hearts submitted to pathological challenges such as myocardial hypertrophy, infarction and hypertension, and under a physiological condition (physical exercise training).
Materials and methods

Animals
Three month-old male Wistar and Sprague-Dawley (SD) rats were used in this study. The animals were provided by the animal facility of the Biological Sciences Institute (CEBIO, Federal University of Minas Gerais) and housed in a temperature (22) (23) (24) • C) and humidity-controlled room maintained on a 12:12-h light-dark schedule with free access to food and water. All animal procedures were performed in accordance with guidelines for the humane use of laboratory animals at our Institute and were approved by local authorities.
Physical training
The exercise training was performed in swimming pools with controlled temperature (31 ± 1 • C) for 40-60 min per day, 5 days per week over 10 weeks. After the first week of adaptation in the swimming pools, Wistar rats (3 month-old, n = 4-6) were submitted to a progressive load test, which consisted of an increasing workload corresponding to 2% of body weight added every 3 min until exhaustion. This test was repeated at the end of the physical training protocol. Exercise intensity of the endurance training was set at 50-80% (second and third weeks: 40-60 min at 50%; fourth week: 40 min at 60%; fifth week: 40 min at 70%; and sixth to tenth weeks: 40-60 min at 80%) of the maximal weight obtained in the progressive test. The maximal weight carried by the animal in the progressive load test was converted to percentage of the animal body weight. Thus, every week the rats were weighed, and using the previously calculated percentage value, a new maximal load was obtained and the 50-80% workload was determined. With this procedure, we eliminated the need for performing the progressive load test on a weekly basis [1] . At the end of the training, the rats were killed by decapitation and the hearts were immediately removed. Left ventricular wet weights were recorded, normalized for body weight and then expressed as cardiac mass index (mg/g). The left ventricles were used for histology and western blot analysis.
Isoproterenol treatment
Wistar rats (n = 4) were daily (7 days) treated with either isoproterenol (2 mg/kg, Sigma-Aldrich) or vehicle (0.9% NaCl, 0.1 ml/100 g, s.c.; control group). At the end of the 7-day period, the rats were killed by decapitation and the hearts were immediately removed. Wet weights of left ventricles were recorded, normalized for body weight and then expressed as cardiac mass index (mg/g). The left ventricles were used for histology and western blot analysis.
DOCA-salt model of hypertension
SD rats (n = 8-10) were nephrectomized (left kidney) under tribromethanol (0.25 g/kg, i.p.) anesthesia. Part of the animals (DOCA) were implanted with a subcutaneous pellet (Silicone rubber encapsulant, Down-Corning) containing deoxycorticosterone acetate (DOCA; 200 mg/kg; Sigma) and had a solution of 0.9% NaCl and 0.2% KCl to drink for 6 weeks, as previously described [21] . Control rats were only uninephrectomized. Systolic arterial pressure (SAP) was evaluated by tail-cuff plethysmography (RTBP2000, Kent Scientific) 1 day before and each 7 days of treatment during 6 weeks. Rats were submitted to echocardiographic evaluation, as previously described [14] . Left ventricular wet weights were recorded, normalized for tibial length and then expressed as cardiac mass index (g/cm). In addition, left ventricles were also used for western blot analysis.
Myocardial infarction
Under anesthesia with 10% ketamine/2% xylazine (4:3, 0.1 ml/100 g, i.p.), Wistar rats (n = 3-5) were placed in the supine position on a surgical table, tracheotomized, intubated and ventilated with room air using a respirator for small rodents. The chest was opened by a left thoracotomy at the fourth or fifth intercostal space. To expose the heart, a small-sized retractor was used to maintain the ribs separated. After incision of the pericardium, the heart was quickly removed from the thoracic cavity and turned left to allow access to the proximal left anterior descending (LAD) coronary artery. A 4-0 silk suture was snared around the LAD and tightly ligated to occlude the vessel. The heart was then placed back and the chest was closed with 4-0 silk sutures. Sham-operated rats were treated in the same manner, but the coronary artery was not ligated. At 7 and 21 days after MI, left ventricular samples were used for western blot analysis.
Histological analysis
Before the sacrifice, the animals were injected with 30 mM KCl to cause cardiac arrest in diastole. Left ventricular samples were kept in 4% Bouin fixative for 24 h at room temperature, dehydrated and imbedded in paraffin. Transversal sections (6 m) were cut at intervals of 40 m and stained with Masson's trichrome to confirm the presence of infarct or with hematoxylin and eosin for cell morphometry, as previously described [6, 14] .
Western blot analysis
Left ventricular samples were homogenized in lysis buffer containing 50 mM sodium pyrophosphate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 2 mM Na 3 VO 4 , 10 mM HEPES pH 7.4, 0.5% Triton 100, 1 mM PMSF, 1 g/ml leupeptin and 1 g/ml aprotinin. Protein concentration of each sample was determined and samples containing 30 g of protein were run on a 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane. Following 1 h blocking with 5% nonfat dry milk in phosphate buffered saline (PBS) containing 0.2% Tween 20 (PBS-T), the membrane was probed with antibody against Mas (1:1000) [2, 20] during 2 h at room temperature. The membranes were washed 4 times for 15 min in PBS-T and incubated with anti-mouse IgG-HRP-conjugated secondary antibody (1:2000) for 1 h. Afterward, the membranes were washed 4 times for 15 min in PBS-T, incubated with chemiluminescent agent (ECL plus, Amersham Biotechnology) for 1 min and exposed to a film to visualize protein bands. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:5000, Santa Cruz Biotechnology) bands were analyzed in parallel and used as a loading control for normalization of the Mas protein levels using the software ImageQuant TM . Mas polyclonal antibody was produced in Mas knockout mice using as antigen a 12 amino acid peptide (LAEEKAMNTSSR) corresponding to the NH 2 -terminal domain of the mouse Mas protein. This sequence has 100% homology with mouse and 91.6% homology with rat Mas and it is not present in any other known protein (see Fasta protein database, www.ebi.ac.uk/fasta33). To confirm our findings we repeated some immunoblotting experiments with a commercial anti-Mas antibody (1:1000, Alomone).
Immunofluorescence
Cardiomyocytes were fixed in 2% paraformaldehyde solution diluted in PBS for 15 min. For immunostaining, cells were incubated with 5% bovine serum albumin (BSA) in PBS containing 5 mg/ml of saponin for 1 h followed by incubation with a polyclonal antibody against Mas raised in Mas deficient mice and diluted at 1:25 [2, 20] . In order to confirm that the entry of the antibody into the cell was achieved, cardiac cells were probed with an antibody against the intracellular Ca 2+ channel, the type 2 ryanodine receptor (RyR2) (diluted 1:50, Affinity BioReagents) overnight at 4 • C. Afterward, they were incubated with goat anti-mouse IgG conjugated with Alexa 633 for 1 h at room temperature. Each step was followed by washing the cells with PBS. The cells were mounted and viewed with a laser scanning confocal microscope (Zeiss 510 Meta-CEMEL ICB, UFMG). All confocal settings (aperture, gain and laser power) were determined at the beginning of the imaging session and these parameters were not changed.
Statistical analysis
All data are expressed as mean ± SEM. Statistical significance was estimated using Student t-test (GraphPad Prism 4.0). The level of significance was set at p < 0.05.
Results
Mas expression in the heart
To evaluate the expression and localization of Mas in isolated ventricular myocytes from adult rats, we used western blotting and immunofluorescence-labeling techniques. As expected, it was observed that Mas is expressed in ventricular myocytes (Fig. 1A) . Testicular samples were used as positive controls. Furthermore, this receptor was mainly localized in the sarcolemma of cardiomyocytes and absent in T-tubules (Fig. 1B) . In order to assess the efficiency of our permeabilization protocol, immunofluorescence was performed using an antibody against RyR2, an intracellular Ca 2+ channel located in the sarcoplasmic reticulum (Fig. 1B) . 
Effects of exercise training on Mas expression in hearts
Physical training was used as a physiological stimulus. Rats subjected to swim training for 1 h 5 days a week during 10 weeks developed significant cardiac hypertrophy as demonstrated by the cardiac mass index (3.41 ± 0.02 mg/g in untrained rats vs. 3.84 ± 0.10 mg/g in trained rats, Fig. 2A ) and by the measurement of cardiomyocyte diameter (10.25 ± 0.55 m in untrained animals vs. 12.50 ± 0.01 m in trained rats, Fig. 2B ). The efficiency of our physical training protocol was further confirmed by the increased time to reach exhaustion at the progressive load test observed in trained rats when compared with untrained group (approximately 87% increase in the trained group, data not shown). In spite of this change in performance, no significant difference in Mas protein levels was observed between left ventricles from sedentary and swim-trained rats ( Fig. 2C and D) .
Effects of isoproterenol treatment on Mas expression in hearts
Cardiac hypertrophy and damage induced by isoproterenol, myocardial infarction and DOCA-salt hypertension were employed to evaluate the response of Mas expression to distinct pathological conditions. Isoproterenol treatment elicited a marked increase in cardiac mass index (3.55 ± 0.17 mg/g in control vs. 4.40 ± 0.10 mg/g in isoproterenol-treated rats, Fig. 3A ). This result was confirmed by the measurement of cardiomyocyte diameter (9.95 ± 0.23 m in control vs. 12.27 ± 2.12 m in isoproterenol-treated rats, Fig. 3B ). Interestingly, this effect was accompanied by a reduction in Mas expression in left ventricles (Fig. 3C and D) .
Effects of DOCA treatment on cardiac Mas expression
Next, we used the DOCA-salt model of hypertension to investigate changes in Mas expression. Three weeks after the start of the DOCA-salt treatment, systolic blood pressure was significantly increased and remained higher until the sixth week of the treatment, as shown in Fig. 4A . We have previously shown that after 4 weeks of DOCA-salt, rats presented increased cardiac ejection fraction when compared to SD control rats [21] . We now extend this finding and show that after 6 weeks of treatment cardiac ejection fraction is still higher in DOCA-salt rats when compared to controls (Fig. 4B) . Marked cardiac hypertrophy was observed at both four and 6 weeks of DOCA-salt treatment (Fig. 4C and D) . Importantly, after 4 weeks of treatment western blot analysis revealed similar expression levels of Mas between DOCA-salt and SD control rats (Fig. 4E ), albeit at 6 weeks Mas expression was significantly increased in left ventricles of DOCA-salt when compared to SD rats (Fig. 4F) .
Effects of myocardial infarction on Mas expression in hearts
Additionally, we investigated changes in Mas expression in hearts at 7 and 21 days post-infarction. Fig. 5A and B shows that cardiac expression of Mas was not different between infarcted and sham-operated rats at 7 days. However, Mas expression was significantly reduced after 21 days of myocardial ischemia when compared with hearts from sham-operated animals ( Fig. 5C and  D) . Masson's trichrome staining for collagen was used to confirm the presence of infarcted area (Supplementary Fig. 1 ).
Discussion
The major finding of the present study is that Mas expression in the heart is regulated according to the stimulus which the animal is submitted, and the stage of the disease. These stimuli include mainly pathological challenges such as myocardial hypertrophy, hypertension and infarction. Recent data have demonstrated that the RAS is composed by two distinct axes, i.e. the hypertensive, hypertrophic and proliferative axis formed by ACE, Ang II and AT 1 receptor and the ACE2/Ang-(1-7)/Mas branch, which has anti-hypertensive, anti-hypertrophic and anti-proliferative actions [23] . Functionally, these two axes have opposite effects, which help to maintain homeostasis of the cardiovascular system. In the current study, we demonstrated that ACE2/Ang-(1-7)/Mas axis can be modulated at receptor level by changing Mas expression in response to different pathophysiological conditions.
In this study, trained Wistar rats were used as a model of physiological cardiac hypertrophy while isoproterenol-treated rats were considered a model of pathological cardiac hypertrophy. The cardiac hypertrophy and the increased time to exhaustion observed in trained Wistar rats indicated that the swimming training protocol used in this study was physiologically efficient. In spite of this and in agreement with our previous study [9] , we did not observe significant changes in Mas expression in the left ventricle of trained normotensive rats. Although the swimming training protocol used here was quite different from the protocol used in our previous study both findings support the notion that physical training alters Mas cardiac expression mainly in diseased states. In fact, Mas expression was increased only in hearts of SHR [9] . Nevertheless, we cannot discard the possibility that the absence of changes in Mas expression in hearts of normotensive rats in response to physical training may be related to the intensity and/or duration of the exercise protocol. Interestingly, if we compare the cardiac mass index of the isoproterenol-injected animals with the index of the physical-trained rats, the hypertrophy induced by the former was higher than the one induced by swimming training. This distinction may also explain the differential modulation of Mas expression observed under these two conditions. Therefore, it is possible that a higher duration and/or intensity of training exercise may lead to a more marked cardiac hypertrophy and possible changes in cardiac Mas expression. Moreover, it should be noted that the signaling pathways activated during the development of physiological hypertrophy induced by physical training are quite different from those activated by pathological stimuli. Along this line, another important point to consider is the evaluation of the cardiac structure. Cardiomyocyte loss with subsequent hypertrophy of the remaining cells is a common alteration found in pathological hypertrophy [7] . In contrast, physical training is generally followed by beneficial cardiomyocyte hypertrophy and reduction in the deposition of fibrotic tissue [19] . We speculate that a distinct expression pattern of Mas in cardiomyocytes and cardiac fibroblasts might explain, at least in part, why physical training did not change the expression of Mas whereas chronic treatment with isoproterenol induced a reduction in cardiac Mas expression.
Next, we used DOCA-salt hypertensive rats and infarcted rats in which cardiac Mas expression was assessed at two different time frames. DOCA-salt rats presented a significant increase in cardiac function and cardiac hypertrophy after 4 and 6 weeks of treatment when compared to control rats. However, cardiac Mas expression in DOCA-salt rats was different from control rats only after 6 weeks of treatment. This result is especially important as it shows that changes in cardiac function or structure are not always accompanied by changes in Mas expression levels. Nevertheless, it is plausible that Mas expression could decrease in DOCA rats with the progression of the disease. In fact, at the time frame investigated in this study DOCA rats were hypertensive with compensated cardiac function, as shown by echocardiography measurements. In this way, evaluation of Mas expression at additional time-points is important in order to further understand the relationship between disease progression and expression of Mas in different experimental models. Since higher or lower levels of Mas expression do not necessarily represent gain or loss of receptor functional activity, it is of fundamental importance to assess in future studies Mas functionality, as well as expression levels of ACE2 and Ang- (1-7) .
Finally, we assessed cardiac Mas expression at 7 and 21 days post-infarction. Interestingly, at the early stage (7 days) cardiac Mas expression did not change when compared to sham group. However, at a later stage (21 days) cardiac Mas expression decreased significantly. In keeping with this finding, Ocaranza et al. [15] have shown that cardiac ACE2 activity decreases with the progression of cardiac disease. Importantly, in this study the authors have demonstrated that cardiac ACE2 activity increases after 1 week of cardiac infarction in rats, while at 8 weeks post injury infarcted rats presented a significant decrease in ACE2 activity when compared to control rats. Thus, these results suggest that ACE2/Ang-(1-7) is generally elevated at the beginning of the establishment of the cardiovascular disease, possibly as an attempt of limiting the damage, while it is depressed in the late phase of disease. In agreement, our study shows that Mas expression levels were altered mainly at a later stage. One possibility is that changes in Mas expression could be a consequence of risk factors and/or events involved in heart dysfunction or diseases, such as pro-inflammatory factors or oxidative stress. In fact, it has been proposed that Ang-(1-7)/Mas counter regulates the pro-inflammatory and increased oxidative stress induced by Ang II/AT 1 receptor [17] . Therefore, it is possible that proinflammatory cytokines and increased oxidative stress, commonly found in disease states, may influence cardiac Mas expression. It is important to note that, in our present study, we cannot rule out the possibility that different rat strains (Wistar vs. Sprague-Dawley) influenced our results since distinct rat strains can respond differently to injury and physical training. Anyway, a different Mas expression pattern was observed in response to various pathological insults with Mas found to be up or down-regulated.
Conclusion
Our present study demonstrated that the expression of Mas is responsive to different pathophysiological stimuli. These findings corroborate the premise that Mas is involved in the homeostasis of the heart and disturbances in its expression may contribute to the establishment and progression of cardiac diseases.
